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Background: Doxorubicin (DOX) produces a cardiomyopathy through multiple mechanisms as Ca2+ overload. DOX generates Reactive Oxigen and 
Nitrogen Species, posing the heart at increased demand for oxygen, setting the stage for metabolic ischemia that activates late sodium current, 
target of ranolazine (RAN). We aim at assessing if RAN, diminishing intracellular Ca2+ through inhibition of late sodium current, prevents DOX 
cardiotoxicity at different levels. 
methods: We measured left ventricular (LV) fractional shortening (FS) with M-mode echocardiography, radial strain by speckle tracking in 
C57BL6 mice, 2-4 mo old, pretreated with RAN (370mg/kg/day, a dose comparable to the one used in humans) per os for 3 days. RAN was then 
administered for additional 7 days, alone and together with DOX (2.17mg/kg/day ip). Hearts were then excised, mRNA expression was analyzed by 
qRT-PCR, interstitial fibrosis with picrosirius red staining. By Western blotting, we measured the activation of the apoptotic pathway.
results: After 7 days with DOX, FS decreased to 50±2%, p=.002 vs 60±1% (sham). RAN alone did not change FS (59±2%). Interestingly, in mice 
treated with RAN+DOX, the reduction in FS was milder: 57±1%, p=.01 vs DOX alone. DOX-cardiotoxicity was accompanied by significant elevations 
in ANP (1000 folds), BNP (500 folds), CTGF (26 folds) and MMP2 (81 folds) mRNAs, while co-treatment with RAN significantly lowered these same 
genes compared to DOX. The alterations in extracellular matrix remodeling were confirmed by an increase of interstitial collagen with DOX (3.66%), 
p=.004 vs 2.19% (sham), which was normal in hearts co-treated with RAN (2.02%, p=.0002 vs DOX). The levels of PARP and pro-Caspase 3 were 
significantly decreased with DOX, with a parallel increase in cleaved caspase 3, but not with RAN+DOX. Radial strain was already decreased after 2 
days of DOX: 34±4%, p=.0003 vs sham (64±4%), but RAN+DOX-treated mice showed a higher value: 49±3%, p=.01 vs DOX alone.
conclusions: In mice, DOX produces LV dysfunction which can be effectively predicted by early radial strain abnormalities. RAN is able to blunt 
such cardiotoxicity at different levels.
